As­traZeneca, Dai­ichi Sankyo eye first ap­proval for TROP2 drug af­ter PhI­II breast can­cer suc­cess

As­traZeneca and Dai­ichi Sankyo’s TROP2-tar­get­ed an­ti­body-drug con­ju­gate has met a key end­point in the Phase III TRO­PI­ON-Breast01 tri­al, bring­ing it one step clos­er to po­ten­tial­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER